NYSE:NVTAInVitae Stock Price, Forecast & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVTA shares have increased by 92.3% and is now trading at $30.48. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InVitae.

InVitae is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for InVitae.

InVitae Corp (NYSE:NVTA) announced its quarterly earnings data on Tuesday, May, 5th. The medical research company reported ($0.80) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.84) by $0.04. The medical research company earned $64.25 million during the quarter, compared to analyst estimates of $59.41 million. InVitae had a negative net margin of 127.42% and a negative return on equity of 69.95%. The firm's revenue was up 58.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.47) earnings per share. View InVitae's earnings history.

5 brokers have issued 1 year price targets for InVitae's shares. Their forecasts range from $20.00 to $35.00. On average, they anticipate InVitae's share price to reach $28.20 in the next twelve months. This suggests that the stock has a possible downside of 7.5%. View analysts' price targets for InVitae.

Headlines about NVTA stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. InVitae earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about InVitae.

Some companies that are related to InVitae include Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), ELEKTA AB/ADR (EKTAY), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Centogene (CNTG), Personalis (PSNL), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Biocept (BIOC) and Anpac Bio-Medical Science (ANPC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Roku (ROKU), Alibaba Group (BABA), Square (SQ), Trade Desk (TTD), Shopify (SHOP), Walt Disney (DIS), salesforce.com (CRM), Twilio (TWLO) and Micron Technology (MU).

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $30.48.

InVitae has a market capitalization of $3.81 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

The official website for InVitae is www.invitae.com.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]